PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Vaccine Development”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,387 records · Page 77Linked to original sources

The genome revolution in vaccine research.

The conventional approach to vaccine development is based on dissection of the pathogen using biochemical, immunological and microbiological methods. Although successful in several cases, this approach has failed to provide a solution to prevent several major bacterial infections. The availability of complete genome sequences in combination with novel advanced technologies, such as bioinformatics, microarrays and proteomics, have revolutionized the approach to vaccine development and provided a new impulse to microbial research. The genomic revolution allows the design of vaccines starting from the prediction of all antigens in silico, independently of their abundance and without the need to grow the pathogen in vitro. This new genome-based approach, which we have named "Reverse Vaccinology", has been successfully applied for Neisseria meningitidis serogroup B for which conventional strategies have failed to provide an efficacious vaccine. The concept of "Reverse Vaccinology" can be easily applied to all the pathogens for which vaccines are not yet available and can be extended to parasites and viruses.

Bacterial Proteins↗

Contraceptive vaccines.

Three major approaches to contraceptive vaccine development are being pursued at the present time. The most advanced approach, which has already reached the stage of phase 2 clinical trials, involves the induction of immunity against human chorionic gonadotrophin (hCG). Vaccines are being engineered based on conjugates incorporating tetanus or diphtheria toxoid linked to a variety of hCG-based peptides centred on the beta-subunit of this molecule. Clinical trials have revealed that such preparations are capable of stimulating the production of anti-hCG antibodies. However, the long term consequences of such immunity in terms of safety or efficacy are, as yet, unknown. The alternative approaches to contraceptive vaccine development involve the induction of immunity against gamete-specific antigens found on the surface of the human spermatozoon or the zona pellucida. There is an abundance of experimental and clinical data to suggest that this approach is feasible although the biochemical characterization and synthesis of candidate antigens is still incomplete.

Animals↗

Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine.

The basis for the development of a vaccine against hepatitis A was laid in the 1970s, when virus was replicated in cell culture. Adaptation to growth in cell culture resulted in attenuation and sufficient quantities of virus particles, allowing the development of both live attenuated and inactivated vaccines. Testing of candidate vaccines in volunteers began in the early 1980s. Recently, a formaldehyde-inactivated whole-virion hepatitis A vaccine, the first licensed vaccine against hepatitis A, was introduced in many countries worldwide, and a live attenuated vaccine became available in the People's Republic of China. Other possible avenues for vaccine development include the use of either conventional or recombinant DNA techniques to obtain subunit vaccines, empty capsids, live viral or bacterial vectors, genetic immunization, synthetic peptides, and anti-idiotypes.

Capsid↗

Lag between discovery and production of new vaccines for the developing world.

Communicable diseases represent a considerable burden in terms of suffering and costs. The decision to develop a new vaccine varies with perspectives. The public health perspective is influenced largely by cost-benefit ratios; the community perspective by a strong desire to alleviate suffering and disability from disease and from vaccine side-effects; and that of vaccine producers by demand, technological feasibility of development, and anticipated return on investment. Each of these perspectives is important. However, they often are mutually exclusive. From a humanitarian and epidemiological perspective, the most urgent needs related to communicable diseases are those of the poorest countries; in the industrialised world, with the exception of the vaccine for the acquired immunodeficiency syndrome (AIDS), public health priorities, evaluated in terms of the cost-benefit ratio, often differ from those of the market, which usually selects its priorities according to return on investment. The six vaccines used in the Expanded Programme of Immunisation (EPI) are offered cheaply through a highly efficient bidding system. It would have to be extended, under the same form or differently, to other vaccines, such as those for rabies, hepatitis B, or japanese encephalitis. For vaccines that are being developed, such as conjugated polysaccharide or acellular pertussis vaccines, it is difficult to foresee how these expensive vaccines can be distributed. The situation is even worse for vaccines to be developed specifically for the third world. To make these vaccines available to everyone there must be technology that enables producers to sharply reduce production costs, and a subsidy for research and development and production.

Cost-Benefit Analysis↗

Novel approaches to control of bacterial infections in animals.

Bacterial infections of poultry remain of great importance world-wide in terms of economic effects and public health. They include infections caused by Salmonella, Escherichia coli, Campylobacter and Pasteurella. Through the introduction of rigid hygienic measures it is possible to breed and rear poultry free of these pathogens. However, the cost to the industry would be prohibitive and economically disastrous. Biological measures have been introduced albeit in a relatively empirical way. Antibiotic therapy and prophylaxis is used extensively with the associated problems of development of resistance. Killed vaccines are used but are not usually very effective. Live vaccines are increasingly becoming acceptable and studies are under way to increase our understanding of the pathogenesis of these infections so that vaccine development may become less empirical. Work with live vaccines to be used against Salmonella has shown that they may be administered orally to newly-hatched chicks. The vaccine strain colonises the gut extensively and prevents re-infection by other Salmonella strains by a genus-specific mechanism which is similar to that which occurs during down-regulation of bacterial growth in stationary-phase nutrient broth cultures. The mechanism of this phenomenon is currently being studied. This approach may also be applied to control Campylobacter infections. Bacteria of the Pasteurella group and E. coli may produce septicaemic infections in poultry. Recent work with K1+ E. coli infections in mice has shown that virulent bacteriophages may be used to treat or prevent septicaemias and meningitides. This work has been extrapolated to chickens with a similar degree of success and it suggests that some infections of this sort in animals and man may be amenable to this approach. In-bred lines of chickens have been found to vary greatly in their susceptibility to systemic Salmonella infections. This is probably mediated by one gene and the effect is dominant and not linked to sex or MHC. The mouse natural resistance gene (NrampI) does not appear to contribute greatly to this effect. Differences in the extent of gut colonisation by Salmonella in in-bred and out-bred lines can also be detected. These results are very exciting and open up opportunities for disease control for the future.

Animals↗

Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

Sexual transmission is the major route for the spread of the human immunodeficiency virus (HIV) in the AIDS pandemic progression. Most attempts to develop a protective HIV vaccine have failed despite eliciting strong systemic immune responses. The basic hypothesis of our poliovirus vaccine vector strategy is that essential requirements for protective immunization against HIV and other related lentiviruses may involve (1) induction of mucosal immunity and (2) immunological responses against multiple viral antigens. To test this hypothesis, we have developed replication-competent poliovirus recombinants, based on the Sabin poliovirus vaccine strain viruses, that carry and express antigens derived from the simian immunodeficiency virus (SIV). Because there are no good immunological correlates for complete protection against SIV infection, we have elected to express the entire SIV genome in defined, discrete overlapping fragments. With this approach all the potentially important antigenic sequences can be effectively expressed at local mucosal sites by the inoculation of a cocktail of recombinant polioviruses that carries a complete set of SIV antigens. Infection of susceptible mice and cynomolgus monkeys with poliovirus-SIV cocktails elicits serum and secretory humoral responses, as well as a strong cellular immunity to the inserted sequences. Most importantly, we have demonstrated that vaccination of cynomolgus monkeys with poliovirus-SIV cocktails protects against infection and AIDS after intravaginal challenge with highly pathogenic SIV(mac)251.

AIDS Vaccines↗

A simple screening method for detecting bindings between oligopeptides and HLA-DR molecules on filter papers: possible application for mapping of putative helper T-cell epitopes on MSP1 of Plasmodium falciparum.

Binding capacities of synthetic peptides to HLA-DR molecules were tested on filter papers to identify putative helper T-cell epitopes on a malarial protein. The antigen tested was the merozoite surface glycoprotein 1 (MSP1) of Plasmodium falciparum, a vaccine candidate targeting the asexual erythrocytic stage. Bindings between synthetic oligopeptides and HLA-DR molecules were tested. Such bindings were not non-specific, and a known helper T-cell epitope peptide showed positive binding to the restricting HLA-DR molecule. By using this screening system, we observed the unequal distribution of HLA-DR-binding peptides in 10 out of 17 MSP1 blocks tested. Block #6 of MSP1 seemed to show the highest frequency in the positive binding; on the other hand, blocks #1 and #17, both of which were thought to be vaccine candidate regions, contained fewer HLA-DR binding peptides. This was not inconsistent with the results that block #17 was less stimulatory to peripheral T cells than block #6. The peptides with positive binding to HLA-DR showed actual epitope activities when we tested peptide-driven proliferation of human bulk T-cell lines, and association between the two parameters was statistically significant (P<0.001). For more detailed information for vaccine development, peptides with both IgG- and HLA-DR binding activities were mapped in block #17 of MSP1. Together with these results, we demonstrate that our simple screening system seems to provide essential information for vaccine development through uncovering locations of putative epitopes for human helper T cells.

Amino Acid Sequence↗

Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies.

This review deals with specific immunotherapy performed with pollen vaccines. Pollen allergens, the immunological mechanism of allergic inflammation and the mechanisms behind successful specific immunotherapy treatment of seasonal pollen allergy shall be discussed. The different approaches to develop improved regimes for specific immunotherapy based on new diagnostic tools, improved pollen vaccines and alternative routes for administration of the vaccines will be highlighted. Diagnostic tools to select patients for specific immunotherapy and for monitoring the treatment are quantitative measurements of allergen-specific immunoglobulin E, G and G4 antibodies and component-resolved diagnostics based on immunoglobulin E binding to individual allergenic components. Future pollen vaccines may consist of hypoallergenic recombinant allergens and T-helper cell type 1-inducing immunostimulatory adjuvants. Both sublingual and nasal administration of pollen vaccines for specific immunotherapy may be used more in future.

Administration, Intranasal↗

Construction of the plasmid pCMV4-rZPC' DNA vaccine and analysis of its contraceptive potential.

Zona pellucida C (ZPC) is a major glycoprotein of the zona pellucida that possesses the sperm receptor function. ZPC induces autoantibody that can block sperm/oocyte interaction. We selected the partial sequence of rabbit ZPC (amino acid 263-415, rZPC') as the target and constructed the pCMV4-rZPC' gene vaccine by using DNA recombinant techniques. The total RNA was extracted from the ovaries of the sexually healthy female rabbit, and the rZPC' cDNA, which was amplified by reverse transcription-polymerase chain reaction, was directly inserted into the cloning vector PCR2.1 to construct the PCR2.1-rZPC'. This insertion fragment was subcloned into the pCMV4 vector to form the pCMV4-rZPC' prototype DNA vaccine. All experimental BALB/C mice and New Zealand rabbits received i.m. injection of pCMV4-rZPC' vaccine three times. The results show that 1) the pCMV4-rZPC' construct expresses rZPC' cDNA in mice muscle cells, 2) 60% of the immunized female mice were infertile at 6 wk after the immunization, 3) the mice immunized with pCMV4-rZPC' DNA vaccine developed anti-rZPC antibodies that bound to the ovarian ZP in situ, and 4) antibodies against rZPC' were also bound to normal animal ovarian ZP in vitro. The results indicate that anti-rZPC antibodies developed from pCMV4-rZPC' DNA vaccine can prevent the fertility course and do not interfere with normal follicular development. The pCMV4-rZPC' DNA vaccine may be possible to develop as a contraceptive vaccine.

Animals↗

Bacterial toxin vaccines.

A rebirth of interest and activity in vaccine development has occurred in recent years which is probably due to the persistence of threat to health by infectious diseases, as well as technological advances which have made possible new approaches to solve old problems. Most work being done today with vaccine development against diseases caused entirely or in part by bacterial toxins falls into the categories of, attenuated organisms (whether by classical means or application of newly developed genetic technologies), and/or toxin subunits (derived by genetic manipulations, peptide synthesis, or chemical modification of toxins). This review discusses some of these new approaches in general as well as specific examples of their application to several bacterial diseases whose pathologies involve toxins.

Animals↗

Varicella: a vaccine preventable disease?

OBJECTIVES: To present a review of varicella disease, vaccine development and implementation of universal vaccination, discuss common questions about the vaccine and the epidemiology of the disease since licensure of the varicella vaccine. METHODS: Review the incidence of complications from varicella disease prior to vaccine licensure, safety of the varicella vaccine from clinical trials and post-marketing surveillance data, the impact of the vaccine on disease incidence where high vaccine coverage has been achieved, and address some barriers to vaccination. Raise issues that developed since 1995. RESULTS: The safety data gathered during the 20-year-gestation period of this vaccine prior to licensure has been confirmed. The vaccine works-in areas where vaccine coverage is over 70%, there has been a decline in disease, most marked in the age group with the best vaccine coverage (the 1-4-year olds), leading to a concern that unexposed susceptible children may reach adulthood and remain susceptible unless better practice of universal vaccination of ALL susceptible is practiced. CONCLUSIONS: Varicella disease has declined in areas with moderate vaccine coverage. Continued implementation of existing vaccine policies will lead to further reductions of varicella morbidity and mortality throughout the USA.

Adolescent↗

[Attempts to develop a vaccine against Ebola fever].

Data on the immunopathogenesis of Ebola fever in laboratory animals are presented and the efficacy of some methods of vaccine prophylaxis discussed. Antiviral immunity induced in guinea pigs by injection of inactivated viral agents did not protect them from infection, whereas injections of a nonlethal strain of the virus in ascending doses led to the formation of immunity preventing the development of disease upon inoculation with a lethal strain in high doses. The role of some viral peptides in the development of immune response is shown and variants of recombinant constructions for the prevention of Ebola fever are offered.

Animals↗

Vaginal immunity in the HSV-2 mouse model.

Herpes simplex virus type 2 (HSV-2) is a sexually transmitted pathogen that infects the genital tract. Efforts to develop vaccines to protect women against this and other sexually transmitted pathogens would be facilitated by a better understanding of the immune mechanisms that protect the female reproductive tract against such infections. Such information would be invaluable in developing vaccine strategies to promote the type and magnitude of immune responses in the genital tract that would effectively protect against infection. This review focuses on recent studies using a progestin-treated adult mouse model to explore mucosal immunity to HSV-2 in the vagina. Evidence indicating a major role for both humoral and T cell immunity is presented.

Animals↗

Clinical and microbiological aspects of Trichomonas vaginalis.

Trichomonas vaginalis, a parasitic protozoan, is the etiologic agent of trichomoniasis, a sexually transmitted disease (STD) of worldwide importance. Trichomoniasis is the most common nonviral STD, and it is associated with many perinatal complications, male and female genitourinary tract infections, and an increased incidence of HIV transmission. Diagnosis is difficult, since the symptoms of trichomoniasis mimic those of other STDs and detection methods lack precision. Although current treatment protocols involving nitroimidazoles are curative, metronidazole resistance is on the rise, outlining the need for research into alternative antibiotics. Vaccine development has been limited by a lack of understanding of the role of the host immune response to T. vaginalis infection. The lack of a good animal model has made it difficult to conduct standardized studies in drug and vaccine development and pathogenesis. Current work on pathogenesis has focused on the host-parasite relationship, in particular the initial events required to establish infection. These studies have illustrated that the pathogenesis of T. vaginalis is indeed very complex and involves adhesion, hemolysis, and soluble factors such as cysteine proteinases and cell-detaching factor. T. vaginalis interaction with the members of the resident vaginal flora, an advanced immune evasion strategy, and certain stress responses enable the organism to survive in its changing environment. Clearly, further research and collaboration will help elucidate these pathogenic mechanisms, and with better knowledge will come improved disease control.

Animals↗